Cuvillier O - Search Results

1

FTY720 (Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular Remodeling, and Chemosensitizes in Renal Cell Carcinoma Animal Model.

Gstalder C, Ader I, Cuvillier O. Gstalder C, et al. Among authors: cuvillier o. Mol Cancer Ther. 2016 Oct;15(10):2465-2474. doi: 10.1158/1535-7163.MCT-16-0167. Epub 2016 Aug 9. Mol Cancer Ther. 2016. PMID: 27507852

2

Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models.

Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V, Mazerolles C, Rischmann P, Teissié J, Malavaud B, Cuvillier O. Pchejetski D, et al. Among authors: cuvillier o. Cancer Res. 2005 Dec 15;65(24):11667-75. doi: 10.1158/0008-5472.CAN-05-2702. Cancer Res. 2005. PMID: 16357178

3

Sphingosine kinase-1--a potential therapeutic target in cancer.

Cuvillier O. Cuvillier O. Anticancer Drugs. 2007 Feb;18(2):105-10. doi: 10.1097/CAD.0b013e328011334d. Anticancer Drugs. 2007. PMID: 17159597 Review.

4

Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models.

Pchejetski D, Doumerc N, Golzio M, Naymark M, Teissié J, Kohama T, Waxman J, Malavaud B, Cuvillier O. Pchejetski D, et al. Among authors: cuvillier o. Mol Cancer Ther. 2008 Jul;7(7):1836-45. doi: 10.1158/1535-7163.MCT-07-2322. Mol Cancer Ther. 2008. PMID: 18644996

5

Sphingosine kinase 1: a new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells.

Ader I, Brizuela L, Bouquerel P, Malavaud B, Cuvillier O. Ader I, et al. Among authors: cuvillier o. Cancer Res. 2008 Oct 15;68(20):8635-42. doi: 10.1158/0008-5472.CAN-08-0917. Cancer Res. 2008. PMID: 18922940

6

Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug.

Guillermet-Guibert J, Davenne L, Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C, Delisle MB, Cuvillier O, Susini C, Bousquet C. Guillermet-Guibert J, et al. Among authors: cuvillier o. Mol Cancer Ther. 2009 Apr;8(4):809-20. doi: 10.1158/1535-7163.MCT-08-1096. Mol Cancer Ther. 2009. PMID: 19372554

7

When the sphingosine kinase 1/sphingosine 1-phosphate pathway meets hypoxia signaling: new targets for cancer therapy.

Ader I, Malavaud B, Cuvillier O. Ader I, et al. Among authors: cuvillier o. Cancer Res. 2009 May 1;69(9):3723-6. doi: 10.1158/0008-5472.CAN-09-0389. Epub 2009 Apr 21. Cancer Res. 2009. PMID: 19383898 Review.

8

Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting.

Cuvillier O, Ader I, Bouquerel P, Brizuela L, Malavaud B, Mazerolles C, Rischmann P. Cuvillier O, et al. Curr Mol Pharmacol. 2010 Jun;3(2):53-65. doi: 10.2174/1874467211003020053. Curr Mol Pharmacol. 2010. PMID: 20302564 Review.

9

The sphingosine kinase-1 survival pathway is a molecular target for the tumor-suppressive tea and wine polyphenols in prostate cancer.

Brizuela L, Dayon A, Doumerc N, Ader I, Golzio M, Izard JC, Hara Y, Malavaud B, Cuvillier O. Brizuela L, et al. Among authors: cuvillier o. FASEB J. 2010 Oct;24(10):3882-94. doi: 10.1096/fj.10-160838. Epub 2010 Jun 3. FASEB J. 2010. PMID: 20522783

10

FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1.

Pchejetski D, Bohler T, Brizuela L, Sauer L, Doumerc N, Golzio M, Salunkhe V, Teissié J, Malavaud B, Waxman J, Cuvillier O. Pchejetski D, et al. Among authors: cuvillier o. Cancer Res. 2010 Nov 1;70(21):8651-61. doi: 10.1158/0008-5472.CAN-10-1388. Epub 2010 Oct 19. Cancer Res. 2010. PMID: 20959468 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

88 results

Search Page

Filters